APO Research
Talk to an analyst

APO RESEARCH · REPORT

Dengue Vaccines

Dengue vaccine is a vaccine used to prevent dengue fever in humans. As of 2019, one version is commercially available, known as CYD-TDV, and sold under the brand name Dengvaxia. The vaccine is only recommended in those who have previously had dengue fever or populations in which most people have been previously infected. The value of the vaccine is limited by the fact that it may worsen outcomes in those who have not previously been infected. It is given as three injections over a year.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Dengue vaccine is a vaccine used to prevent dengue fever in humans. As of 2019, one version is commercially available, known as CYD-TDV, and sold under the brand name Dengvaxia. The vaccine is only recommended in those who have previously had dengue fever or populations in which most people have been previously infected. The value of the vaccine is limited by the fact that it may worsen outcomes in those who have not previously been infected. It is given as three injections over a year.

Selected research

Market Outlook & Growth Opportunities

Global Dengue Vaccines Market Outlook and Growth Opportunities 2026

27 December 2025191 pages

Choose your research edition.

Industry ResearchDengue Vaccines Industry Research Report 2026102 pages · $2,950 USDIndustry Growth & TrendsGlobal Dengue Vaccines Industry Growth and Trends Forecast to 203260 pages · $3,450 USDMarket StructureGlobal Dengue Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032175 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dengue Vaccines Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Dengue Vaccines Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Dengue vaccine is a vaccine used to prevent dengue fever in humans. As of 2019, one version is commercially available, known as CYD-TDV, and sold under the brand name Dengvaxia. The vaccine is only recommended in those who have previously had dengue fever or populations in which most people have been previously infected. The value of the vaccine is limited by the fact that it may worsen outcomes in those who have not previously been infected. It is given as three injections over a year.

The only one version which is commercially available now, known as Dengvaxia and produced by Sanofi, don't has enough efficacy. While there are several vaccines are on trial now. TAK-003, developed by Takeda is one stride closer to reaching the sizable market waiting for dengue vaccines as it reports positive top-line results from a massive Phase III trial.

This report provides an overview of the global Dengue Vaccines market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Dengue Vaccines and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Dengue Vaccines revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Dengue Vaccines market.

Dengue Vaccines Segment by Company

Sanofi

Takeda

Dengue Vaccines Segment by Type

Dengvaxia

TAK-003

Others

Dengue Vaccines Segment by Application

Public Sector

Private Sector

Dengue Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Dengue Vaccines status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Dengue Vaccines key companies, revenue, market share, and recent developments.

3. To split the Dengue Vaccines breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Dengue Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Dengue Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze Dengue Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dengue Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dengue Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dengue Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Dengue Vaccines industry.

Chapter 3: Detailed analysis of Dengue Vaccines company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Dengue Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Dengue Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Dengue Vaccines Industry Trends Table 2. Dengue Vaccines Industry Drivers Table 3. Dengue Vaccines Industry Opportunities and Challenges Table 4. Dengue Vaccines Industry Restraints Table 5. Global Dengue Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Dengue Vaccines Revenue Share by Company (2021-2026) Table 7. Global Dengue Vaccines Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Dengue Vaccines Key Company Manufacturing Base & Headquarters Table 9. Global Dengue Vaccines Company, Product Type & Application Table 10. Global Dengue Vaccines Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Dengue Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Dengvaxia Table 15. Significant Companies of TAK-003 Table 16. Significant Companies of Others Table 17. Global Dengue Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Dengue Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Dengue Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Dengue Vaccines Sales Value Share by Type (2021-2026) Table 21. Global Dengue Vaccines Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Public Sector Table 23. Significant Companies of Private Sector Table 24. Global Dengue Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Dengue Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Dengue Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Dengue Vaccines Sales Value Share by Application (2021-2026) Table 28. Global Dengue Vaccines Sales Value Share by Application (2027-2032) Table 29. Global Dengue Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Dengue Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Dengue Vaccines Sales Value Share by Region (2021-2026) Table 32. Global Dengue Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Dengue Vaccines Sales Value Share by Region (2027-2032) Table 34. Global Dengue Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Dengue Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Dengue Vaccines Sales Value Market Share by Country (2021-2026) Table 37. Global Dengue Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Dengue Vaccines Sales Value Market Share by Country (2027-2032) Table 39. Sanofi Company Information Table 40. Sanofi Business Overview Table 41. Sanofi Dengue Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Sanofi Dengue Vaccines Product Portfolio Table 43. Sanofi Recent Development Table 44. Takeda Company Information Table 45. Takeda Business Overview Table 46. Takeda Dengue Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Takeda Dengue Vaccines Product Portfolio Table 48. Takeda Recent Development Table 49. Research Programs/Design for This Report Table 50. Authors List of This Report Table 51. Secondary Sources Table 52. Primary Sources List of Figures Figure 1. Dengue Vaccines Product Image Figure 2. Global Dengue Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dengue Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global Dengue Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Dengvaxia Image Figure 8. TAK-003 Image Figure 9. Others Image Figure 10. Global Dengue Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Dengue Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Dengue Vaccines Sales Value Share by Type (2021-2032) Figure 13. Public Sector Image Figure 14. Private Sector Image Figure 15. Global Dengue Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Dengue Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Dengue Vaccines Sales Value Share by Application (2021-2032) Figure 18. Global Dengue Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Dengue Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Dengue Vaccines Sales Value (2021-2032) & (US$ Million) Figure 21. North America Dengue Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Dengue Vaccines Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Dengue Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Dengue Vaccines Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Dengue Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Dengue Vaccines Sales Value (2021-2032) & (US$ Million) Figure 27. South America Dengue Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Dengue Vaccines Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Dengue Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Dengue Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Dengue Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Dengue Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Dengvaxia
  • TAK-003
  • Others
Applications
  • Public Sector
  • Private Sector
Companies covered
  • Sanofi
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Dengue Vaccines Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Dengue Vaccines Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Dengue Vaccines Market Dynamics
  1. 2.1 Dengue Vaccines Industry Trends
  2. 2.2 Dengue Vaccines Industry Drivers
  3. 2.3 Dengue Vaccines Industry Opportunities and Challenges
  4. 2.4 Dengue Vaccines Industry Restraints
3 Dengue Vaccines Market by Company
  1. 3.1 Global Dengue Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global Dengue Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global Dengue Vaccines Company Ranking (2024-2026)
  4. 3.4 Global Dengue Vaccines Company Manufacturing Base and Headquarters
  5. 3.5 Global Dengue Vaccines Company Product Type and Application
  6. 3.6 Global Dengue Vaccines Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Dengue Vaccines Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Dengue Vaccines Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Dengue Vaccines Market by Type
  1. 4.1 Dengue Vaccines Type Introduction
  2. 4.1.1 Dengvaxia
  3. 4.1.2 TAK-003
  4. 4.1.3 Others
  5. 4.2 Global Dengue Vaccines Sales Value by Type
  6. 4.2.1 Global Dengue Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Dengue Vaccines Sales Value by Type (2021-2032)
  8. 4.2.3 Global Dengue Vaccines Sales Value Share by Type (2021-2032)
5 Dengue Vaccines Market by Application
  1. 5.1 Dengue Vaccines Application Introduction
  2. 5.1.1 Public Sector
  3. 5.1.2 Private Sector
  4. 5.2 Global Dengue Vaccines Sales Value by Application
  5. 5.2.1 Global Dengue Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Dengue Vaccines Sales Value by Application (2021-2032)
  7. 5.2.3 Global Dengue Vaccines Sales Value Share by Application (2021-2032)
6 Dengue Vaccines Regional Value Analysis
  1. 6.1 Global Dengue Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Dengue Vaccines Sales Value by Region (2021-2032)
  3. 6.2.1 Global Dengue Vaccines Sales Value by Region: 2021-2026
  4. 6.2.2 Global Dengue Vaccines Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Dengue Vaccines Sales Value (2021-2032)
  7. 6.3.2 North America Dengue Vaccines Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Dengue Vaccines Sales Value (2021-2032)
  10. 6.4.2 Europe Dengue Vaccines Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Dengue Vaccines Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Dengue Vaccines Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Dengue Vaccines Sales Value (2021-2032)
  16. 6.6.2 South America Dengue Vaccines Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Dengue Vaccines Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Dengue Vaccines Sales Value Share by Country, 2025 VS 2032
7 Dengue Vaccines Country-level Value Analysis
  1. 7.1 Global Dengue Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Dengue Vaccines Sales Value by Country (2021-2032)
  3. 7.2.1 Global Dengue Vaccines Sales Value by Country (2021-2026)
  4. 7.2.2 Global Dengue Vaccines Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Dengue Vaccines Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Dengue Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Dengue Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Dengue Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Dengue Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Dengue Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Dengue Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Dengue Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Dengue Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Dengue Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Dengue Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Dengue Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Dengue Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Dengue Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Dengue Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Dengue Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Dengue Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Dengue Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Dengue Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Dengue Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Dengue Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Dengue Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Dengue Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Dengue Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Dengue Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Dengue Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Dengue Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Dengue Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Dengue Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Dengue Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Dengue Vaccines Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Dengue Vaccines Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Takeda
  8. 8.2.1 Takeda Company Information
  9. 8.2.2 Takeda Business Overview
  10. 8.2.3 Takeda Dengue Vaccines Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Takeda Dengue Vaccines Product Portfolio
  12. 8.2.5 Takeda Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst